The REGROW Act is a bill that seeks to lessen the regulatory burden to accelerate getting stem cells to patients more quickly, but it over-reaches so much that it would almost certainly do harm to patients and maybe to the stem cell field as a whole. The REGROW Act, which is sponsored by Senator Mark […]
REGROW Act 2.0 still no-go with big risks to patients & field Read More »
ISSCR 2016’s first plenary session is focused on stem cells & cancer. I was really excited about this one even before the meeting as this topic is a major focus of my own lab. Here’s the lineup for this plenary with great expertise in stem cells & cancer from across the globe: President’s Address: Sean Morrison, Children’s
Austin Smith talk at ISSCR 2016: a ground state inhibitor pathway Read More »
Today a new Nature paper from Dr. Mary Herbert’s group in the UK has found a key problem with mitochondrial replacement therapy that fits with data from others. Mitochondrial replacement data The goal of preventing mitochondrial disease using various kinds of genome transfer technologies is a noble one, but mitochondrial replacement therapy has faced a
New Herbert lab Nature paper reinforces mitochondrial replacement Achilles heel Read More »
The gene editing technology CRISPR has been arguably the top story in the biomedical world in the last two years, but going forward there is a CRISPR challenger in upstart gene editing technology NgAgo. For more background on NgAgo and the key first published paper on its genetic modification characteristics see my post here. In the comments on that
NgAgo a-go-go: main bullet points on upstart CRISPR challenger Read More »
Haruko Obokata is most well-known for her role as first author of the now retracted two STAP cell Nature papers. These manuscripts claimed to have made pluripotent and even totipotent stem cells simply by stressing cells out with acid treatment or in other ways. Nobody else could get this method to work to create the so-called
Haruko Obokata (小保方 晴子) website posts dubious STAP cell validation data Read More »
Why can there be huge clinical trial fees for participants? I am often critical of for-profit stem cell clinics on this blog for numerous reasons. For instance, one thing that concerns me greatly about these clinics is that they charge patients to get experimental “treatments” that have not been proven to be safe or effective. But
Huge clinical trial fees allowed by FDA at times, details often secret Read More »
An important new Cell Stem Cell paper from Dieter Egli’s lab points to an inherent, serious problem with so-called 3-person IVF or mitochondrial replacement technology that warrants putting an immediate hold on all efforts to use it in humans. I have pasted the graphical abstract from the paper below. For years a few of us scientists and
UK should freeze mitochondrial replacement as Egli paper ID’s serious problem Read More »
2020 Update: early NgAgo reports have been mostly discredited and there is doubt on its function as a gene-editing method. What could be better than CRISPR for gene editing? A new genetic modification technology called NgAgo has some researchers really excited. How does it compare to CRISPR? I’ll admit it that as a scientist who works on
Will new gene editing tech NgAgo challenge CRISPR? Read More »
Editor’s note. Caroline Simons attended both the April 28th (see her report on that here) and 29th Paris meetings on human gene editing/genetic modification. Today, we have her in depth report on the April 29th meeting. I have posted her piece in full with only minor edits. If you are in a rush you can
In Depth Report from April 29th Paris Human Gene Editing Meeting Read More »
Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of
Paris human gene editing workshop summary Read More »